GLPG Galapagos NV Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

GLPG [NASD]

Galapagos NV

Healthcare | Biotechnology | Belgium

statements

Index	-	P/E	-	EPS (ttm)	-1.69	Insider Own	-	Shs Outstand	65.25M	Perf Week	-0.01%
Market Cap	8.94B	Forward P/E	-	EPS next Y	-1.73	Insider Trans	-	Shs Float	41.57M	Perf Month	1.64%
Income	-	PEG	-	EPS next Q	-0.77	Inst Own	11.71%	Short Float	2.42%	Perf Quarter	-31.64%
Sales	-	P/S	-	EPS this Y	-137.00%	Inst Trans	-	Short Ratio	7.47	Perf Half Y	-22.06%
Book/sh	25.49	P/B	5.38	EPS next Y	-69.60%	ROA	-	Target Price	215.70	Perf Year	-11.93%
Cash/sh	-	P/C	-	EPS next 5Y	0.60%	ROE	-	52W Range	112.00 - 274.03	Perf YTD	-33.74%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-49.99%	Beta	-
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	22.36%	ATR	5.89
Employees	1130	Current Ratio	-	Sales Q/Q	161.30%	Oper. Margin	-	RSI (14)	42.20	Volatility	2.24% 2.75%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.93	Prev Close	137.44
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	134.80K	Price	137.04
Recom	2.50	SMA20	3.38%	SMA50	-16.89%	SMA200	-31.14%	Volume	125,497	Change	-0.29%

Aug-25-20

Downgrade

Jefferies

Buy → Hold

Aug-24-20

Downgrade

H.C. Wainwright

Buy → Neutral

$270 → $123

Aug-19-20

Upgrade

Citigroup

Neutral → Buy

Aug-19-20

Downgrade

Barclays

Overweight → Equal Weight

Jul-10-20

Downgrade

Stifel

Buy → Hold

$298 → $193

Mar-30-20

Upgrade

Jefferies

Hold → Buy

$232

Mar-18-20

Upgrade

RBC Capital Mkts

Underperform → Sector Perform

$175 → $157

Feb-25-20

Downgrade

Cantor Fitzgerald

Overweight → Neutral

Feb-24-20

Downgrade

BofA/Merrill

Neutral → Underperform

Feb-20-20

Downgrade

RBC Capital Mkts

Sector Perform → Underperform

$175

Jan-06-20

Downgrade

JP Morgan

Overweight → Neutral

Dec-18-19

Downgrade

Citigroup

Buy → Neutral

Dec-17-19

Downgrade

Morgan Stanley

Overweight → Equal-Weight

Dec-13-19

Downgrade

Credit Suisse

Outperform → Neutral

$174 → $169

Dec-02-19

Initiated

BofA/Merrill

Neutral

Sep-09-19

Resumed

Morgan Stanley

Overweight

Jul-31-19

Upgrade

UBS

Neutral → Buy

Jul-29-19

Downgrade

Jefferies

Buy → Hold

Jul-15-19

Reiterated

H.C. Wainwright

Buy

$150 → $205

Jul-10-19

Resumed

Credit Suisse

Outperform

Sep-18-20 04:01PM	Galapagos increases share capital through subscription right exercises GlobeNewswire
Sep-14-20 10:28AM	Gilead Just Made a Big Bet on Immunomedics Cancer Treatment. Was the Price too High? Barrons.com
09:28AM	Galapagos (GLPG) Surges: Stock Moves 8.8% Higher Zacks
05:45AM	Galapagos Pops 9% On Positive Result Of Novesa Trial SmarterAnalyst
Sep-13-20 06:17PM	Gilead's $21 Billion Deal Splurge May End in Regret Bloomberg
Sep-11-20 08:05AM	The Daily Biotech Pulse: Positive Readout From Galapagos, Intersect ENT Strikes Distribution Deal, Sol Gel's Regulatory Filing Accepted For Review Benzinga +8.78%
Sep-10-20 10:30PM	Primary endpoint achieved with ziritaxestat in NOVESA trial in systemic sclerosis patients GlobeNewswire
Sep-01-20 11:15PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG ACCESSWIRE
Aug-28-20 07:45AM	Remdesivir Data Leaves Gilead Stock Well-Positioned to Rally InvestorPlace
06:10AM	Why I Gave Up on Gilead Motley Fool
Aug-26-20 01:30AM	Galapagos to present new insights in IPF and related clinical developments at the European Respiratory Society Congress GlobeNewswire
Aug-25-20 10:45PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG GlobeNewswire
Aug-21-20 01:54AM	StockBeat: Galapagos' Halo Slips Investing.com
Aug-20-20 05:28PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG GlobeNewswire
11:45AM	Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Galapagos NV (GLPG) Investigation ACCESSWIRE
Aug-19-20 08:01PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG PR Newswire -25.03%
12:18PM	Why Galapagos Stock Is Crashing Today Motley Fool
12:00PM	Two Surprising FDA Rejections Raise Alarms for Biotech Investors Bloomberg
10:42AM	Potential Gilead Blockbusters Were Rejected By the FDA. Why Thats the Near-Worst-Case Scenario for the Stock. Barrons.com
03:46AM	Gilead arthritis drug won't be approved by FDA in current form, partner Galapagos says MarketWatch
02:48AM	Gilead Sinks After-Hours As FDA Rejects Rheumatoid Arthritis Application SmarterAnalyst
12:29AM	Gilead's Rheumatoid Arthritis Drug Application Is A No-Go In Present Form: FDA Benzinga
Aug-18-20 07:25PM	Galapagos announces that Gilead received a complete response letter for filgotinib for the treatment of moderately to severely active rheumatoid arthritis GlobeNewswire
Aug-12-20 04:01PM	Scipher Medicine and Galapagos sign collaboration in inflammatory bowel disease GlobeNewswire
Aug-06-20 04:01PM	Galapagos reports solid H1 2020 progress GlobeNewswire
Jul-24-20 08:14AM	GILEAD AND GALAPAGOS ANNOUNCE POSITIVE EUROPEAN CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS GlobeNewswire
08:10AM	Gilead and Galapagos Announce Positive European CHMP Opinion for Jyseleca® (Filgotinib) for the Treatment of Adults With Moderate to Severe Rheumatoid Arthritis Business Wire
Jul-07-20 06:48PM	5 Greenblatt Magic Formula Biotech Stocks to Weather the Summer Coronavirus Storm GuruFocus.com
Jul-02-20 10:38AM	Better Buy: Vertex Pharmaceuticals vs. Galapagos Motley Fool
Jun-26-20 12:31PM	Hedge Funds Are Warming Up To Galapagos NV (GLPG) Insider Monkey
Jun-07-20 11:15AM	AstraZeneca Ponders a Huge $240 Billion Gilead Gamble Bloomberg
Jun-05-20 04:01PM	New Analyses of Phase 2 EQUATOR Clinical Program Support Durable Efficacy of Filgotinib in Psoriatic Arthritis Business Wire
Jun-04-20 10:03AM	Stocks in Europe slip ahead of ECB decision MarketWatch
03:19AM	Galapagos shares rise on Phase 3 studies of arthritis drug it's making with Gilead MarketWatch
01:29AM	Filgotinib Demonstrates Durable Efficacy and Consistent Safety Profile at 52 Weeks in FINCH 1 and 3 Studies in Rheumatoid Arthritis Business Wire
May-21-20 11:20AM	Galapagos and Gilead Sciences Post Successful Yet Disappointing Filgotinib Results Motley Fool -7.76%
08:01AM	The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive Benzinga
05:17AM	Gilead, Galapagos Announce Positive Data on Inflammatory Drug Zacks
02:37AM	Gilead and Galapagos Score Positive Topline Results For Ulcerative Colitis Trial SmarterAnalyst
May-20-20 04:03PM	Gilead and Galapagos Announce Positive Topline Results of Phase 2b/3 Trial of Filgotinib in Moderately to Severely Active Ulcerative Colitis Business Wire
May-11-20 06:52AM	H.C. Wainwright Sticks to Their Buy Rating for Galapagos NV Investing.com +6.51%
May-09-20 10:00PM	Galapagos NV (GLPG) Q1 2020 Earnings Call Transcript Motley Fool
Apr-25-20 11:56AM	7 stock picks for a volatile market from a manager who finds innovation all over the place MarketWatch
Apr-24-20 11:41AM	7 Beautiful Biotech Stocks to Buy Here InvestorPlace
Apr-22-20 09:07AM	Why Galapagos (GLPG) Might Surprise This Earnings Season Zacks
Apr-16-20 02:12AM	Galapagos and Ryvu Announce Research Collaboration PR Newswire
Mar-18-20 02:29PM	Top Biotech Stocks for Q2 2020 Investopedia -5.36%
Mar-17-20 02:38PM	Hedge Funds Were Buying Galapagos NV (GLPG) Before The Coronavirus Insider Monkey
Mar-06-20 06:10AM	5 Biotech Stocks to Buy for a Strong Growth Prognosis InvestorPlace
Feb-05-20 09:21AM	Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat Zacks
09:15AM	Vertex (VRTX) Hits 52-Week High, Can the Run Continue? Zacks
Jan-16-20 10:34AM	Big Pharma Remains Accused of Keeping Prices High. That Wont Change Soon. Barrons.com
07:22AM	The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics Benzinga
Jan-15-20 08:22AM	The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance Benzinga
Jan-06-20 10:21AM	Buy Sanofi Stock Because Its Undervalued, J.P. Morgan Says Barrons.com
Jan-03-20 05:43PM	2020 Preview: The year ahead in Bay Area biotech and health American City Business Journals
Dec-26-19 10:26AM	Gilead (GILD) Partners With Eisai for RA Candidate in Japan Zacks
Dec-20-19 08:27AM	Gilead (GILD) Files NDA With FDA for RA Candidate Filgotinib Zacks
Dec-13-19 04:06PM	Is Galapagos NV (GLPG) A Good Stock To Buy? Insider Monkey
Dec-03-19 03:42PM	Hedge Funds Love Vereit Inc (VER) Way More Than These 4 Stocks Insider Monkey
Dec-02-19 02:57PM	7 Exciting Biotech Stocks to Buy Now InvestorPlace
Nov-13-19 07:34AM	Is Galapagos NV's (AMS:GLPG) CEO Pay Justified? Simply Wall St.
Nov-09-19 04:30PM	New Data on Filgotinib in Rheumatoid Arthritis (RA) Demonstrate Durable Efficacy and Safety Profile Business Wire
Oct-31-19 04:01PM	Gilead and Galapagos to Present New Data on Filgotinib at 2019 ACR/ARP Annual Meeting Business Wire
Oct-25-19 10:36AM	Gilead's (GILD) Earnings Miss Estimates in Q3, Sales Beat Zacks
Oct-23-19 10:06AM	Were Hedge Funds Right About Overlooking Galapagos NV (GLPG)? Insider Monkey
Oct-18-19 11:22AM	New Gilead CFO: Let's Make a Deal GuruFocus.com
11:17AM	Will Strong HIV Sales Drive Gilead's (GILD) Q3 Earnings? Zacks
Oct-16-19 04:00AM	HitGen Enters into DNA-Encoded Library Based Drug Discovery Research Collaboration with Galapagos NV Business Wire
Oct-11-19 09:19AM	Gilead-Galapagos Report Efficacy & Safety Results on RA Drug Zacks
08:14AM	The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout Benzinga
Oct-10-19 06:00PM	Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in FINCH 1 and FINCH 3 Studies in Rheumatoid Arthritis Business Wire
Oct-09-19 11:10AM	Gilead (GILD) Files NDA for RA Candidate Filgotinib in Japan Zacks
Sep-26-19 12:38PM	Foreign Firms Recognized as Hottest Biotechs GuruFocus.com
Sep-03-19 05:46PM	Top-Performing Biotech ETFs YTD Zacks
Aug-29-19 09:00AM	Galapagos NV (GLPG) Upgraded to Buy: Here's What You Should Know Zacks
Aug-28-19 10:34AM	Biotech Stock Roundup: AMGN to Buy CELG's Otezla, ALXN's Soliris Gets EC Nod & More Zacks
Aug-26-19 08:28AM	Gilead & Galapagos Close Research & Development Agreement Zacks
Aug-23-19 04:01PM	Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration Business Wire
Aug-16-19 09:19AM	Gilead's (GILD) Filgotinib MAA for RA Accepted in Europe Zacks
Aug-15-19 04:01PM	European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis Business Wire
Aug-05-19 01:08PM	Here's Why Galapagos NV Rose 34.5% in July Motley Fool
Jul-31-19 09:55AM	Gilead (GILD) Q2 Earnings & Sales Beat, Sales Guidance Raised Zacks
Jul-29-19 04:43PM	Marijuana Stock Cann('t)Trust, and What's Behind Gilead's Latest Megadeal Motley Fool
Jul-26-19 06:23PM	Galapagos NV (GLPG) Q2 2019 Earnings Call Transcript Motley Fool
11:50AM	Will Strong HIV Sales Drive Gilead's (GILD) Q2 Earnings? Zacks
10:11AM	Top Ranked Momentum Stocks to Buy for July 26th Zacks
Jul-22-19 10:37AM	Galapagos NV (GLPG) Shares March Higher, Can It Continue? Zacks
Jul-18-19 04:02PM	Transparency notification GlobeNewswire
Jul-17-19 10:06AM	Biotech Stock Roundup: Galapagos & Hookipa Surge, AMGN Shelves Alzheimer's Study Zacks
07:15AM	Gilead's Galapagos Deal: What It Means for Investors Motley Fool
Jul-16-19 09:50AM	Company News for Jul 16, 2019 Zacks
Jul-15-19 07:40PM	Gilead Sciences, Inc. -- Moody's: Gilead's collaboration with Galapagos credit positive Moody's +17.16%
05:34PM	Wall Street Mixed on Monday GuruFocus.com
04:50PM	What Happened in the Stock Market Today Motley Fool
04:48PM	Nasdaq Today: Bitcoin & Libra; Whats Broadcom Doing? InvestorPlace
04:26PM	Stocks eke out another round of records as investors brace for 2nd-quarter earnings MarketWatch
02:32PM	Galapagos Deal: GLPG Stock Rockets Higher on Gilead Stake InvestorPlace
10:22AM	Gilead Risks Regrets on Pricey Galapagos Partnership Bloomberg
10:01AM	Galapagos Notches $3.95B Upfront Investment From Gilead Benzinga

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjogren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.a r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience